CULLINAN THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.88 USD | -1.09% |
|
-4.94% | +164.47% |
| May. 09 | Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing | MT |
| Apr. 29 | Cullinan Therapeutics Appoints Mary Kay Fenton as CFO | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 2.14M | Sales 2025 * | 13.04M | Capitalization | 1.17B |
|---|---|---|---|---|---|
| Net income 2024 * | -175M | Net income 2025 * | -189M | EV / Sales 2024 * | 257 x |
| Net cash position 2024 * | 619M | Net cash position 2025 * | 538M | EV / Sales 2025 * | 48.4 x |
| P/E ratio 2024 * |
-8
x | P/E ratio 2025 * |
-8.57
x | Employees | 85 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.6% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cullinan Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -1.98% | ||
| 1 week | -1.49% | ||
| Current month | +0.59% | ||
| 1 month | +59.54% | ||
| 3 months | +45.29% | ||
| 6 months | +183.32% | ||
| Current year | +166.63% |
1 week
26.96
30.19
1 month
15.2030.19
Current year
10.0030.19
1 year
7.6430.19
3 years
7.3037.66
5 years
7.3059.85
10 years
7.3059.85
| Managers | Title | Age | Since |
|---|---|---|---|
Nadim Ahmed
CEO | Chief Executive Officer | 56 | 21-10-17 |
Jeffrey Jones
CTO | Chief Tech/Sci/R&D Officer | 53 | 22-02-27 |
Jacquelyn Sumer
CMP | Compliance Officer | 46 | 22-08-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 17-07-31 | |
Thomas Ebeling
BRD | Director/Board Member | 65 | 17-07-31 |
Stephen Webster
BRD | Director/Board Member | 63 | 20-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 26.91 | -0.96% | 426 715 |
| 24-05-09 | 27.17 | -1.98% | 1,224,765 |
| 24-05-08 | 27.72 | -5.55% | 1,031,724 |
| 24-05-07 | 29.35 | +3.35% | 873,483 |
| 24-05-06 | 28.4 | +0.18% | 767,160 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
27.17
USD
Average target price
33.12
USD
Spread / Average Target
+21.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +166.63% | 1.17B | |
| +23.37% | 47.02B | |
| +49.79% | 41.86B | |
| -0.94% | 41.76B | |
| -4.32% | 28.8B | |
| +11.29% | 26.05B | |
| -20.92% | 19.15B | |
| +3.20% | 12.55B | |
| -2.67% | 11.82B | |
| +30.23% | 12.34B |
- Stock Market
- Equities
- CGEM Stock